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Background: Infections due to multi-drug resistant gram negative bacilli (RGNB) in critically ill patients have been
reported to be associated with increased morbidity and costs and only a few studies have been done in Asia. We
examined the financial impact of nosocomial RGNB infections among critically ill patients in Singapore.
Methods: A nested case control study was done for patients at medical and surgical ICUs of a tertiary university
hospital (August 2007-December 2011) matched by propensity scores. Two groups of propensity-matched controls
were selected for each case patient with nosocomial drug resistant gram negative infection: at-risk patients with no
gram negative infection or colonization (Control A) and patients with ICU acquired susceptible gram negative
infection (SGNB) (Control B). The costs of the hospital stay, laboratory tests and antibiotics prescribed as well as
length of stay were compared using the Wilcoxon matched-pairs signed rank test.
Results: Of the 1539 patients included in the analysis, 76 and 65 patients had ICU acquired RGNB and SGNB
infection respectively. The median(range) total hospital bill per day for patients with RGNB infection was 1.5 times
higher than at-risk patients without GNB infection [Singapore dollars 2637.8 (458.7-20610.3) vs. 1757.4 (179.9-6107.4),
p0.0001]. The same trend was observed when compared with SGNB infected patients. The median costs per day of
antibiotics and laboratory investigations were also found to be significantly higher for patients with RGNB infection.
The length of stay post infection was not found to be different between those infected with RGNB and SGNB.
Conclusion: The economic burden of RGNB infections to the patients and the hospital is considerable. Efforts need
to be taken to prevent their occurrence by cost effective infection control practices.
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Critically ill patients have been shown to have higher
risk of nosocomial infection compared to other hospital-
ized patients [1]. Intensive Care units have been identi-
fied as the epicenter of not just nosocomial infections
but also of drug resistant infections [2]. These difficult to
treat drug resistant organisms were named as “ESKAPE”
pathogens [3] or in the words of the Infectious Diseases
Society of America as “Bad bugs, no drugs”. While* Correspondence: amapuna_76@yahoo.com
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unless otherwise stated.resistance among gram positive isolates has been stable or
decreasing globally, it has been rising among nosocomial
gram negative isolates [4]. This is especially so in the ICU
[5]. Organisms such as Klebsiella spp., Escherichia Coli,
Acinetobacter baumanii, Pseudomonas aeruginosa and
Stenotrophomonas maltophilia often have decreased sus-
ceptibility to many antibiotics making them difficult to
treat [6]. In Singapore, third generation cephalosporin
resistant Klebsiella pneumoniae were found to be the
predominant organisms among the intensive care unit
(ICU) isolates in a recent study [7].
Nosocomial infections in general are associated with
increased hospital costs, causing a financial burden totral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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sistance they are believed to have a significant economic
impact [9]. Even among less severely ill patients, drug
resistant infections increase total hospitalization costs
[10]. Studies which documented costs of nosocomial re-
sistant gram negative bacilli (RGNB) infections have gener-
ally considered site or organism specific RGNB infections
and often included all hospitalized patients [11,12]. To our
knowledge, very little has been published addressing the
costs of nosocomial RGNB infections in ICUs.
Most of the previous studies are case control or obser-
vational studies where obtaining a comparable group of
controls is critical. Matching by use of specific variables
may not completely help eradicate bias as there may be
other confounding factors not matched for and it is also
possible to “over-match” cases and controls. It has been
shown that matching by propensity scores results in better
selection of a comparator group with less bias [13,14].
Propensity scores aid in estimating the likelihood of
patients in the ICU being infected with RGNB based on a
risk factor analysis thus taking multiple relevant risk
factors into consideration.
We therefore designed the current study to estimate the
excess cost associated with nosocomial ICU acquired
RGNB infection (any site) among critically ill patients
using a propensity score matched case–control approach.
Methods
Setting
A nested case control study was performed within a pro-
spective cohort study conducted at the medical and sur-
gical ICU of a 1000-bed tertiary hospital affiliated to the
National University of Singapore from August 2007
through December 2011 [15]. The prospective study in-
cluded all consecutive adult patients over 21 years of age
who had been admitted for more than 24 hours to either
the medical or surgical ICU. The following data were
collected prospectively for each patient: demographics,
co-morbidities, APACHE II, Charlson scores, invasive
devices, antibiotics used, any surgical procedure per-
formed, culture results and total hospitalization costs
along with individual costs of laboratory and radiological
investigations, medications including antibiotics.
The study was approved by the Institutional Domain
Specific Review Board (B/06/140) with a waiver of consent.
Definition
Resistant Gram Negative Bacilli (RGNB): Acinetobacter
baumannii, Pseudomonas aeruginosa, Klebsiella pneu-
moniae, Escherichia coli were the organisms of interest:
Multi-drug resistance in these organisms was defined as
being non susceptible to > =1 agent in > =3 antimicrobial
categories based on the European Centers of Disease
control categorization [16].Colonization: All patients with RGNB cultured from
any clinical specimen with no associated clinical signs or
symptoms of infection with no treatment initiated by the
clinician, or documentation as colonization by an infec-
tious disease specialist [17].
Infection: All patients with RGNB cultured from any of
the clinical specimens who were treated for RGNB infec-
tion according to the National Health and Safety Network’s
definitions of infection [17].
Nosocomial ICU acquired RGNB infection: RGNB iso-
lated after 48 hours of admission to the ICU.
Costs: Total hospitalization costs were obtained from
the hospital financial records based on charges paid by
the patient or their insurers inclusive of government
subsidies.
Cases: Patients with Nosocomial ICU acquired RGNB
infection
Controls: Patients with no GNB infection or colonization
(Control A) or Nosocomial ICU acquired SGNB infection
(Control B).
Selection of cases and controls - propensity score
matching
Propensity score calculation: Propensity scores were cal-
culated using the independent risk factors for Nosoco-
mial RGNB infection acquired in the ICU identified in
our study by a multivariable logistic regression analysis.
Gender was also included in the final model for calcula-
tion of propensity scores.
Selection of controls
Two sets of controls were selected for these case
patients.
At-risk patients with no GNB infection or colonization
(Control A): patients with nosocomial ICU acquired
RGNB infection (case) were matched with patients with
no GNB infection or colonization (control A) by the
nearest neighbor matching method without replacement
in a ratio of 1:1.
Patients with nosocomial ICU acquired SGNB infection
(Control B): patients with nosocomial ICU acquired RGNB
infection with no previous SGNB infection/colonization
this admission (case) were matched with patients with
nosocomial ICU acquired SGNB infection (control B) by
the nearest neighbor matching method with replacement
in a ratio of 1:1. We employed matching with replacement
as the numbers of patients with SGNB infections were lim-
ited. Controls (control B) were matched for cases with no
previous SGNB infection/colonization this admission in
order to control for the compounding treatment costs of a
previous SGNB infection.
Balance checks were conducted between the propen-
sity score matched cases and controls to ensure quality
matching so as to decrease the bias.
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The costs per day were used in order to correct for the
effects of mortality which may shorten the length of stay
of the most severely ill patients.
Total hospital costs per day: For each case and each
control, the total bill for the entire hospital stay was
obtained through the hospital finance system and was
divided by the number of total hospital stay in days to
obtain the hospital costs per day.
Costs per day from date of ICU admission: We ob-
tained the costs from date of ICU admission for each pa-
tient and divided them by the number of hospital days
counting from ICU admission.
Costs per day from date of infection: For each case
and Control B (SGNB infection), the costs were obtained
from date of infection and were divided by the number
of days the patient stayed in the hospital from the date
of infection.
The same approach was repeated for obtaining the
costs per day for the different categories.
Length of stay analysis
Including the ICU survivors of the nosocomial RGNB
infection, we investigated differences in the length of stay
between the cases and the 2 different controls. Hospital
stay from the date of admission to ICU was used in the
analysis for those without infection. In addition, we also
compared the length of hospital stay post infection for
cases and Control B (SGNB infection).
Statistical analysis
Analysis was done using STATA 10.1(STATA Corp,
Texas, USA). The costs between the cases and controls
(A & B) were compared using student’s paired t-test orFigure 1 Patient inclusion chart.Wilcoxon matched-pair signed rank tests where applic-
able. Separate analyses were done to compare cases with
the two different control groups.
Results
A total of 2949 patients were enrolled in our study. Ex-
cluding patients with a GNB isolate before or within
48 hours of admission to the ICU, any GNB colonization
in the ICU and those with SGNB isolates after discharge
from the ICU and non-SIRS patients, a total of 1539 pa-
tients were included in the analysis. Of these, 76 and 65
patients had a laboratory confirmed nosocomial ICU ac-
quired RGNB and SGNB infection respectively (Figure 1).
Propensity score calculation
Among patients with SIRS, we identified the following
risk factors to be independently associated with the oc-
currence of nosocomial ICU acquired RGNB infection
when compared to patients with no GNB colonization
or infection by logistic regression analysis- a stay of
more than 5 days in the ICU, presence of any GNB, ad-
ministration of carbapenems in the past 6 months, having
a surgical procedure during this admission and end stage
renal disease on dialysis [18]. Gender was added to this
model and propensity scores were then calculated [14].
Seventy-one out of 76 case patients had complete de-
tails of the costs for their admission and were analyzed.
Control selection
Control A: 71 control patients were chosen from the cohort
of patients with SIRS and no GNB infection/colonization
(n = 1398) using the propensity scores obtained from the
logistic model. One control per case was chosen without
replacement.
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tion, 51 of them had no SGNB isolated this admission
prior to the RGNB infection and were further analyzed
for this case control portion of the study. Controls
were chosen from the cohort of patients with ICUTable 1 Patient characteristics: analysis A: cases and







Male 43 (60.6%) 47 (66.2%)
Female 28 (39.4%) 24 (33.8%)
Intensive care unit (ICU) 0.11
Medical ICU 45 (63.4%) 35 (50%)
Surgical ICU 26 (36.6%) 35 (70%)
Admission to the ICU 0.61
Direct admission 35 (49.3%) 38 (53.5%)
Transfer from the ward 36 (50.7%) 33 (46.5%)
Diabetes 27 (38%) 21 (29.6%) 0.29
Renal impairment 17 (23.9%) 13 (18.3%) 0.41
Cerebrovascular accident 7 (9.9%) 12 (16.9%) 0.22
Peptic ulcer disease 4 (5.6%) 0 (0%) 0.12
Myocardial infarction 12 (16.9%) 10 (14.1%) 0.64
Congestive cardiac failure 1 (1.4%) 4 (5.6%) 0.37
Liver disease 2 (2.8%) 3 (4.2%) 1
Malignancy 14 (19.7%) 8 (11.3%) 0.61
Central venous catheter 43 (60.6%) 54 (76.1%) 0.08
Endotracheal intubation 66 (92.9%) 71 (100%) 0.09
Mean days of duration of
mechanical ventilation (SD)
5.8 (SD4.7) 4.7 (SD3.9) 0.14
Prior SGNB** infection
or colonization in the previous
6 months months
18 (25.4%) 21 (29.6%) 0.57
Prior Carbapenems in
the past 6 months




46 (64.8%) 36 (50.7%) 0.12
Surgery prior to RGNB*** infection 35 (49.3%) 39 (54.9%) 0.61
Stay in ICU for more than 5 days 51 (71.8%) 55 (77.5%) 0.56
Mortality 36 (50.7%) 18 (25.4%) 0.003
Mean age (SD) 60.6 (SD1.8) 59.1 (SD17.9) 0.58
Mean APACHEII (SD) 18.1 (SD7.3) 19.6 (SD7.7) 0.24
Mean age adjusted
Charlson score (SD)
3.4 (SD2.9) 3.1 (SD2.9) 0.56
Median PreICU stay (range) 1 (0–40) 0 (0–29) 0.54
Mean propensity scores (SD) 0.15 (SD0.2) 0.14 (SD0.2) 0.92
**Sensitive Gram Negative Bacilli ***Resistant Gram Negative Bacilli.acquired SGNB infection (n = 65) in a ratio of 1:1 with
replacement. 49 of the 51 cases had complete cost
details. Table 1 and Table 2 shows the characteristics
of cases and controls involved in the two analyses.Table 2 Patient characteristics: analysis B: cases and







Male 32 (65.3%) 31 (63.3%)
Female 17 (34.7%) 18 (36.7%)
Intensive care unit (ICU) 0.61
Medical ICU 26 (53.1%) 22 (47.8%)
Surgical ICU 23 (46.9%) 24 (52.2%)
Admission to the ICU 0.54
Direct admission 27 (55.1%) 24 (48.9%)
Transfer from the ward 22 (44.9%) 25 (51.1%)
Diabetes 15 (30.6%) 13 (26.5%) 0.66
Renal impairment 9 (18.4%) 13 (26.5%) 0.33
Cerebrovascular accident 5 (10.2%) 12 (24.5%) 0.11
Peptic ulcer disease 3 (6.1%) 1 (2.1%) 0.62
Myocardial infarction 8 (16.3%) 9 (18.4%) 0.79
Congestive cardiac failure 3 (6.1%) 0 (0%) 0.24
Liver disease 2 (4.1%) 1 (2.1%) 1
Malignancy 4 (8.2%) 0 (0%) 0.12
Central venous catheter 45 (91.8%) 45 (91.8%) 1
Endotracheal intubation 49 (100%) 47 (95.9%) 0.49
Mean days of duration
of mechanical
ventilation (SD)
7.9 (SD6.8) 7.6 (SD2.9) 0.80
Prior SGNB** infection
or colonization in
the past 6 months
3 (6.1%) 0 (0%) 0.24
Prior Carbapenems in
the past 6 months
23 (46.9%) 23 (46.9%) 1
Prior 3rd generation
Cephalosporins in
the past 6 months
25 (51.1%) 15 (30.6%) 0.05
Surgery prior to
RGNB*** infection
23 (46.9%) 27 (55.1%) 0.42
Stay in ICU for more
than 5 days
38 (77.6%) 37 (75.5%) 0.81
Mortality 28 (57.1%) 15 (30.6%) 0.008
Mean age (SD) 59.5 (SD18.2) 57.1 (SD16.4) 0.5
Mean APACHEII (SD) 20.4 (SD7.2) 20.6 (SD5.8) 0.88
Mean age adjusted
Charlson score (SD)
3.5 (SD3.1) 3.2 (SD2.7) 0.62
Median PreICU stay (range) 0 (0–25) 1 (0–32) 0.21
Mean propensity scores (SD) 0.58 (SD0.24) 0.58 (SD0.24) 0.99
**Sensitive Gram Negative Bacilli ***Resistant Gram Negative Bacilli.
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A Wilcoxon matched pair signed rank test was done to
compare the costs per day for the propensity matched
cases and controls for both the analyses.
Comparison of the costs between patients with RGNB
infection and no GNB infection (Table 3) showed that
the median total hospital costs per day and the costs in
all the categories especially the cost of carbapenems
were significantly higher for cases.
Similarly, comparing cases with RGNB infections with
their propensity matched control patients with SGNB
infection (Control B), we found that the median costs
per day of for RGNB infected patient were significantly
higher in all the categories (Table 4).
Length of stay analysis
There were 35 survivors among nosocomial ICU RGNB
acquired infected patients. A comparison of the length
of stay in the hospital after ICU admission between the
Cases and Controls A showed that cases infected with
RGNB stayed longer in the hospital. The details are
shown in Table 5.
Among the 35 survivors, 21 of them had no SGNB iso-
lated during the current admission and were included in
the analysis to assess the difference in the LOS. When the
cases were compared with patients infected with SGNB
(Control B), we found that the there was no difference in
the total length of stay at the hospital, after admission to
the ICU and after Infection between the RGNB infected
cases and SGNB infected Control B (Table 6).
Discussion
Our propensity matched case control study showed that
patients with nosocomial ICU acquired RGNB infection
encountered markedly increased hospital costs when
compared with patients with no GNB infection and
those with SGNB infection. The median per day costs of
laboratory tests and antibiotics were 1.5-2 times higher
than that of patients with no GNB infection and were
nearly 3 times more than for SGNB infected patients.
In a previous analysis of ICU infections, nearly 80% of
the hospital costs were contributed by an ICU stay ofTable 3 Analysis A: comparison of costs between the propens
Costs per day (S$) RGNB (n = 71)
Median total hospitalization costs (range) 2637.8 (458.7-20
After admission to the ICU
Median laboratory costs (range) 381.7 (68.9-3366
Median investigation costs (range) 145.3 (27.8-1663
Median total medication costs (range) 332.7 (48.3-8625
Median antibiotics costs (range) 69.9 (0.93- 334.7
Median carbapenem costs (range) 22.31 (0–223.53)more than 5 days [19]. In our study, we found that the
costs of RGNB infection were higher even after adjusting
for the length of stay in the ICU. We also did not find
an increase in length of stay for patients infected with
RGNB compared with patients infected with SGNB. This
suggests that it is the costs of treatment rather than sim-
ply the prolonging of hospitalization that increases the
cost of antimicrobial resistance. While the economic im-
pact of MRSA has long been recognized, the importance
of resistant gram-negative bacilli is only recently being
recognized. A retrospective study from Austria found
that the total hospital costs for patients infected with
RGNB were significantly higher than for patients with
MRSA partly because of the costs of ICU care [20]. A
retrospective study from Spain, also showed that the total
hospital costs of patients with resistant and multidrug re-
sistant Pseudomonas aeruginosa were 1.4 times and 1.7
times more than those patients with the non-resistant
Pseudomonas aeruginosa [21]. In our study, we have noted
a comparable rate of increased costs associated with
nosocomial ICU acquired RGNB infection. While there
are many new drugs recently licensed for the treatment of
resistant gram-positive infections, no new agents are avail-
able for multi-resistant gram-negative infections. Older
drugs such as colistin are increasingly being used as well
as costly combinations of drugs.
Overall, in our propensity score matched cost analysis
we found that nosocomial multi-resistant infections add
significantly to the already heavy financial burden of pa-
tients in the ICU and their providers in Asia as has been
previously reported in Europe and North America [22-24].
A recent study involving patients with RGNB bacteremia
done in Singapore at two tertiary care hospitals showed
that RGNB bacteremia contributed significantly to higher
hospitalization costs for patients in general. The bulk
(62.3%) of the excess cost was paid for by government
subvention [25].
Although clinicians especially those working in ICUs
have long recognized increasing antimicrobial resistance
rates and decreasing options for treatment, this has not
been widely recognized in the wider medical community
and more importantly among funders and policy makers.ity matched cases and controls A
no GNB (n = 71) p value
610.3) 1757.4 (179.9-6107.4) 0.0001
.5) 252.2 (0.06-1037.8) <0.001
.8) 108.7 (0–452.6) 0.007
.1) 147.6 (0.08-1478.9) <0.001
) 32.3 (0–305.4) 0.001
0 (0–210.2) <0.001
Table 4 analysis B: comparison of costs between the propensity matched cases and controls B
Costs per day (S$) RGNB (n = 49) SGNB (n = 49) p value
Median total hospitalization costs (range) 2795.9 (506.9-4882.3) 2009.6 (857.5-5213.5) 0.0004
After admission to the ICU
Median laboratory costs (range) 392.5 (111.1-1911.4) 203.53 (92.3-823.9) <0.001
203.53 (92.3-823.9)
Median investigation costs(range) 147.4 (40.7-515.4) 93.9 (37.5-528.6) 0.03
Median total medication costs (range) 347.6 (87.6-1753.9) 372 (57.8-1698.9) 0.13
Median antibiotics costs (range) 82.5 (8.9-269) 39.1 (0.28-173.7) 0.004
Median Carbapenem costs (range) 35.73 (0–218.3) 12.9 (0–146.8) 0.0002
After infection
Median laboratory costs (range) 412.4 (53.76-4029.4) 109.8 (57.3-1131.6) <0.001
Median investigation costs (range) 109.2 (8.6-559) 64.1 (0–279.2) 0.002
Median total medication costs (range) 584.4 (91.4-9633.6) 200.7 (53.2-1761.8) 0.0002
Median antibiotics costs (range) 146.1 (15.7-3491.9) 39.5 (0.85-572.9) 0.0001
Median Carbapenem costs (range) 56.38 (0–2040.88) 10.47 (0–211.98) <0.001
Table 6 Comparison of length of stay between the
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(WAAAR), Inter Academy Panel and Inter Academy
Medical Panel (IAP-IAMP), ReAct, Infectious Diseases
Society of America(IDSA) and Alliance for the Prudent
Use of Antibiotics (APUA) are some of the global alliances
assembled by academics and clinicians to try to reduce
antimicrobial resistance [26]. Some government linked
agencies such as the Centers for Disease Control and
Prevention(CDC), WHO and the European Commission
[27-29] have also devised strategies to reduce antimicro-
bial resistance but the WHO has pointed out that the ef-
forts are often fragmented and lack a solid evidence base
[30]. Partnership with politicians and policy makers is cru-
cial to mobilize resources to control the spread of drug re-
sistance. Quality data demonstrating the economic impact
of these resistant organisms would help to convince policy
makers to invest in cost effective control measures to con-
tain them. With rising healthcare costs in almost every
country worldwide, these are very important consider-
ations. Governments and funders need to be aware of
these costs which could be the impetus for novel funding
mechanisms to support the development of much needed
therapeutics for RGNB. Economic analyses have helpedTable 5 Comparison of length of stay between the







Median days in hospital (range) 41 (13–301) 22 (7–198) 0.01
After admission to the ICU
Median days in hospital (range) 37 (13–301) 17 (2–107) 0.01drive public policy in other areas. For example, screen-
ing for colorectal cancer has been shown to be cost
effective and also more importantly to reduce mortality
[31]. This has now become national policy in most
developed countries.
The increased costs attributable to the presence of
nosocomial drug resistant gram negative bacilli infections
among critically ill patients that we have documented
helps make the case that there is a strong economic im-
perative to reduce these infections. With fewer antibiotics
in the pipeline for drug resistant gram negative infections,
controlling their incidence and spread becomes even more
important [32].
To our knowledge, no one has previously examined
the economic impact of RGNB infections in an ICU
population using a propensity score approach. As it
would be impossible and unethical to randomize pa-
tients to be infected with multi-resistant organisms, the
main modality used to study these infections has been







Median days in hospital (range) 34 (13–301) 43 (7–156) 0.39
After admission to the ICU
Median days in hospital (range) 34 (13–301) 42 (7–124) 0.41
After infection
Median days in hospital (range) 24 (2–294) 33 (1–97) 0.29
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control group with similar characteristics to the RGNB in-
fected patients, we employed a propensity score matching
technique to reduce bias in the analysis. This has been
shown in other settings to be useful [34]. We intended to
capture only those patients with ICU acquired nosocomial
resistant gram negative infection as this has been the trig-
ger for calls for broad spectrum initial antibiotic therapy
for all patients with the systemic inflammatory response
syndrome in ICUs. The actual number of these patients
with a proven resistant ICU acquired gram-negative infec-
tion turned out to be low despite reviewing nearly 2000
ICU admissions and hence we ended with a small sample
size. Larger multi-center studies should be conducted to
validate our findings.
Other potential limitations are that the study was done
at a single center and we measured only the direct costs
borne by the patient and funders. We did not include
the indirect costs including the, opportunity costs such
as loss of bed days for the hospital or the additional
costs of follow-up outpatient visits and loss of earnings
for the patient.
Conclusion
Nosocomial acquired RGNB infections increase the total
hospital costs in ICU patients. Urgent measures need to
be taken to design cost-effective strategies to decrease
the spread of these drug resistant infections.
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